New Drugs 2017 by The Rx Consultant

New Drugs 2017 is organized by The Rx Consultant and will be held from Mar 22, 2018 - Mar 22, 2021.

Target Audience:
This accredited program is targeted to pharmacists and nurses.

Accreditation:
• 2.0 CE
• 0.20 CEU

Conference Description:
New Drugs 2017: In 2017, 46 new medicines were approved by the FDA – the highest number of approvals in 21 years. Scott Gottlieb, who was sworn in as FDA Commissioner in May 2017, has made use of policy changes put into effect during recent years to accelerate the approval process. This issue of The Rx Consultant focuses on new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: venous thromboembolism prophylaxis, atopic dermatitis, hepatitis C infection, psoriasis, HER2-positive breast cancer, Parkinson disease, Huntington disease, tardive dyskinesia, and bacterial vaginosis.

Two new glaucoma medications are summarized in the online appendix. Dosing, drug interactions, and pronunciation guides are shown in Table 1. Brief descriptions of 14 additional new drugs are included in Table 2.

Goals and Objectives:
At the conclusion of this program, participants will be able to: 
• For each of the drugs reviewed:
? List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy.
? Describe significant side effects and drug interactions. Provide 2-3 patient counseling tips
• For drugs listed in Table 2:
? List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.

Additional details will be posted as soon as they are available.